Glycation and advanced glycation end-product formation with icodextrin and dextrose.
OBJECTIVE
To review protein glycation and advanced glycation end-product formation with particular reference to its occurrence in the peritoneum following exposure to peritoneal dialysis fluid.


METHODS
Articles identified through searches on MEDLINE and BIDS and references cited therein.


METHODS
Studies on the interaction of amino groups with glucose, maltose and glucose polymers. Studies containing evidence of peritoneal advanced glycation end-product formation.


METHODS
Studies evaluated as to whether they are in vivo, ex vivo or in vitro under non-physiological or physiological conditions.


RESULTS
Protein glycation is slower with maltose and glucose polymers than with equimolar glucose. Advanced glycation end-product formation occurs with all three sugars, but to a greater extent after standard heat sterilization of dialysis fluid and to a lesser extent in heat sterilized fluids containing icodextrin rather than glucose. Glucose degradation products significantly contribute to protein-linked advanced glycation end-product-like fluorescence. Histology and immunohistochemistry demonstrate diabetiform changes and advanced glycation end-products in the peritoneal membrane following exposure to glucose-containing peritoneal dialysis fluids. Their presence is likely to be detrimental to peritoneal function and may contribute to loss of ultrafiltration.


CONCLUSIONS
Advanced glycation end-product formation is lower but still significant with heat sterilized peritoneal dialysis fluid containing icodextrin than with glucose. More research is needed to investigate the interaction of glucose degradation products and glucose polymers with proteins and the possible consequences of advanced glycation end-product formation on peritoneal function.
Dawnay
A B
AB
Department of Clinical Biochemistry, St. Bartholomew's Hospital, London, England.
Millar
D J
DJ
D015314:Dialysis Solutions / Q000494:pharmacology*; D005936:Glucans / Q000494:pharmacology*; D005947:Glucose / Q000494:pharmacology*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D000077607:Icodextrin; D066298:In Vitro Techniques; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000378:metabolism
D015314:Dialysis Solutions; D005936:Glucans; D017127:Glycation End Products, Advanced; D000077607:Icodextrin; D005947:Glucose